Skip to main content

Main menu

  • Home
  • Our journals
    • Clinical Medicine
    • Future Healthcare Journal
  • Subject collections
  • About the RCP
  • Contact us

Clinical Medicine Journal

  • ClinMed Home
  • Content
    • Current
    • Ahead of print
    • Archive
  • Author guidance
    • Instructions for authors
    • Submit online
  • About ClinMed
    • Scope
    • Editorial board
    • Policies
    • Information for reviewers
    • Advertising

User menu

  • Log in

Search

  • Advanced search
RCP Journals
Home
  • Log in
  • Home
  • Our journals
    • Clinical Medicine
    • Future Healthcare Journal
  • Subject collections
  • About the RCP
  • Contact us
Advanced

Clinical Medicine Journal

clinmedicine Logo
  • ClinMed Home
  • Content
    • Current
    • Ahead of print
    • Archive
  • Author guidance
    • Instructions for authors
    • Submit online
  • About ClinMed
    • Scope
    • Editorial board
    • Policies
    • Information for reviewers
    • Advertising

Cancer immunotherapy and the management of side effects

Darran Mc Donald
Download PDF
DOI: https://doi.org/10.7861/clinmed.Let.23.2.1
Clin Med March 2023
Darran Mc Donald
University of Galway, Galway, Ireland
Roles: Specialist registrar in endocrinology
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Editor – We thank Mahalingam and Newsom-Davis1 for their overview of immunotherapy side effects and in particular immunotherapy-related endocrinopathies. Immunotherapy has revolutionised the treatment of numerous malignancies in recent years. This paradigm shift poses a challenge to oncologists and general internal physicians who are exposed to a range of immunotherapy-related endocrinopathies which may be outside their usual area of expertise. It is important that clinicians acquire the knowledge and skills necessary to manage to these side effects appropriately.

Mahalingam and Newsom-Davis' review1 discusses the management of immunotherapy-related hypothyroidism. It is essential that clinicians must first differentiate primary hypothyroidism (due to thyroiditis) from secondary hypothyroidism (due to hypophysitis), which is defined as a low or inappropriately normal thyroid stimulating hormone (TSH) in the setting of a low free T4. Although thyroxine replacement is the appropriate treatment for primary hypothyroidism it risks precipitating an adrenal crisis in those with immunotherapy-related hypophysitis.2 ACTH deficiency is the most commonly affected pituitary hormone deficit followed by TSH, with deficiency rates of 91% and 84% respectively in those receiving anti-CTLA-4 treatment.3 Therefore, the presence of secondary hypothyroidism should raise immediate concern for adrenal insufficiency. Administration of thyroxine in this circumstance can precipitate an adrenal crisis as thyroxine increases the metabolism of (already deficient) cortisol.4 An urgent assessment of the hypothalamic-pituitary-adrenal (HPA) axis with measurement of ACTH and cortisol is mandatory in patients presenting with secondary hypothyroidism. Once confirmed, hydrocortisone replacement should be initiated followed by thyroxine replacement at least 48 hours after.2 In acutely unwell patients, hydrocortisone should be administered empirically prior to an assessment of the HPA axis.

It is also important for general physicians to note that thyroxine should be titrated to maintain a fT4 level in the upper half of the normal range. TSH cannot be used to titrate thyroxine in this setting as it will invariably be low. Although this may seem obvious, we frequently encounter patients with secondary hypothyroidism whose dose of thyroxine has been reduced as a low TSH is misinterpreted as thyroxine overreplacement rather than secondary hypothyroidism. We hope this letter will contribute to the improved understanding around the management of immunotherapy-related hypothyroidism.

  • © Royal College of Physicians 2023. All rights reserved.

References

  1. ↵
    1. Mahalingam P
    , Thomas Newsom-Davis T. Cancer immunotherapy and the management of side effects. Clin Med 2023;23:56–60.
    OpenUrlAbstract/FREE Full Text
  2. ↵
    1. Fleseriu M
    , Hashim IA, Karavitaki N, et al. Hormonal replacement in hypopituitarism in adults: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2016;101:3888–921.
    OpenUrlCrossRefPubMed
  3. ↵
    1. Caturegli P
    , Di Dalmazi G, Lombardi M, et al. Hypophysitis secondary to cytotoxic T-lymphocyte–associated protein 4 blockade: insights into pathogenesis from an autopsy series. Am J Pathol 2016;186:3225–35.
    OpenUrlCrossRefPubMed
  4. ↵
    1. McDonald D
    , Goulden E, Cullen G, Crown J, Crowley RK. Myxoedema coma caused by immunotherapy-related thyroiditis and enteritis. Endocrinol Diabetes Metab Case Rep 2021;2021:21–0130.
    OpenUrl
Back to top
Previous articleNext article

Article Tools

Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Citation Tools
Cancer immunotherapy and the management of side effects
Darran Mc Donald
Clinical Medicine Mar 2023, 23 (2) 190; DOI: 10.7861/clinmed.Let.23.2.1

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Cancer immunotherapy and the management of side effects
Darran Mc Donald
Clinical Medicine Mar 2023, 23 (2) 190; DOI: 10.7861/clinmed.Let.23.2.1
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • References
  • Info & Metrics

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Mitigating the hazards of false dichotomies
  • ChatGPT in medical practice, education and research: malpractice and plagiarism
  • Where now for infection services in the NHS? What about children?
Show more Letters to the editor

Similar Articles

FAQs

  • Difficulty logging in.

There is currently no login required to access the journals. Please go to the home page and simply click on the edition that you wish to read. If you are still unable to access the content you require, please let us know through the 'Contact us' page.

  • Can't find the CME questionnaire.

The read-only self-assessment questionnaire (SAQ) can be found after the CME section in each edition of Clinical Medicine. RCP members and fellows (using their login details for the main RCP website) are able to access the full SAQ with answers and are awarded 2 CPD points upon successful (8/10) completion from:  https://cme.rcplondon.ac.uk

Navigate this Journal

  • Journal Home
  • Current Issue
  • Ahead of Print
  • Archive

Related Links

  • ClinMed - Home
  • FHJ - Home
clinmedicine Footer Logo
  • Home
  • Journals
  • Contact us
  • Advertise
HighWire Press, Inc.

Follow Us:

  • Follow HighWire Origins on Twitter
  • Visit HighWire Origins on Facebook

Copyright © 2021 by the Royal College of Physicians